In a US study, the mean increase in Hb after 28–52 weeks was 0.39 g/dg/dL in the group of CKD patients treated with roxadustat compared to 0.09 g/dg/dL in the group of CKD patients treated with erythropoietin alfa. This evidence concerns the gene GSTM1 and chronic kidney disease.